Physician profile
Jenna M Daffer
NPI 1215569942
$1,322.92
in general payments reported to CMS, 2019-2025
16 companies · $157 in 2025
The $157 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2.83 · 2023: $848 · 2024: $315 · 2025: $157.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,061 · Education: $259.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,061.15 |
| Education | $258.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seagen INC. | $161.63 | 2023 | Tukysa |
| Novartis Pharmaceuticals Corporation | $146.91 | 2023-2025 | |
| Janssen Biotech, INC. | $146.65 | 2023-2024 | Imbruvica, Tecvayli, Talvey |
| Amgen INC. | $146.47 | 2023 | Lumakras |
| Regeneron Healthcare Solutions, INC. | $136.13 | 2023 | Libtayo |
| Astrazeneca Pharmaceuticals LP | $127.99 | 2023-2025 | Calquence, Enhertu |
| Ipsen Biopharmaceuticals, INC | $125.10 | 2023 | Tazverik |
| Incyte Corporation | $99.00 | 2024 | |
| Daiichi Sankyo INC. | $60.33 | 2024-2025 | Enhertu, Injectafer |
| Genentech USA, INC. | $52.55 | 2023-2025 | Tecentriq |
| Pfizer INC. | $29.18 | 2024 | |
| Rigel Pharmaceuticals, INC. | $25.89 | 2024 | Tavalisse, Rezlidhia |
| Pharmaessentia USA Corporation | $24.40 | 2025 | Besremi |
| Array Biopharma INC | $21.63 | 2025 | Mektovi, Tukysa, Braftovi |
| Merck Sharp & Dohme LLC | $16.23 | 2025 | Lynparza, Keytruda |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Quidel Corporation | $2.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenna Daffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.